### Edgar Filing: ALLERGAN INC - Form 4

ALLERGAN Form 4 June 06, 201											
FORM									PPROVAL		
	UNITED	STATES					E COMMISSION	N OMB Number:	3235-0287		
Washington, D.C. 20549Check this box if no longer subject to Section 16.STATEMENT OF CHANGES IN BENEFICIAL OWN SECURITIESForm 4 or Form 5 obligations may continue. See Instruction 1(b).STATEMENT OF CHANGES IN BENEFICIAL OWN 								Expires:       January 31, 2005         Estimated average       burden hours per response         0.5			
(Print or Type ]	Responses)										
1. Name and Address of Reporting Person <u>*</u> Dunsire Deborah			Symbol	er Name <b>an</b> o RGAN IN			5. Relationship of Reporting Person(s) to Issuer				
			ALLERGAN INC [AGN]				(Check all applicable)				
(Last) (First) (Middle) 2525 DUPONT DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 06/04/2014				X_ Director10% Owner Officer (give titleOther (specify below)below)				
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>					
IRVINE, C.	A 92612						Form filed by Person	More than One R	eporting		
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivati	ve Securities A	Acquired, Disposed	of, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution I any (Month/Day	Date, if	3. Transactio Code (Instr. 8) Code V	Dispos (Instr. 3	ed (A) or ed of (D) 3, 4 and 5) (A) or	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Rep	oort on a separate line	e for each cla	ss of sect	urities bene	Per info req disp	sons who resormation con uired to resp	or indirectly. spond to the colle tained in this form ond unless the fo ntly valid OMB co	i are not rm	SEC 1474 (9-02)		

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exercisable and	7. Title and Amount of	8. Price
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onof	Expiration Date	Underlying Securities	Derivati
Security	or Exercise		any	Code	Derivative	(Month/Day/Year)	(Instr. 3 and 4)	Security
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Securities			(Instr. 5

#### Edgar Filing: ALLERGAN INC - Form 4

	Derivative Security		Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ed						
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Phantom Stock Units	<u>(1)</u>	06/04/2014	А		15.1 (2)		(3)	(3)	Common Stock	15.1	\$ 165

## **Reporting Owners**

Reporting Owner Name / Address		Relationsh		
	Director	10% Owner	Officer	Other
Dunsire Deborah 2525 DUPONT DRIVE IRVINE, CA 92612	Х			
Signatures				
/s/ Matthew J. Maletta, Attorne	y-in-Fact	for Deborah	1	

Dunsire

\*\*Signature of Reporting Person

06/06/2014

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Converts to common stock on a 1-for-1 basis.
- (2) Phantom stock units acquired under the Allergan, Inc. Deferred Directors' Fee Program.
- (3) Phantom stock units are to be settled 100% in common stock upon the Reporting Person's retirement as an Allergan, Inc. director.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.